Postmenopausal Osteoporosis, tolerability, efficacy, Bisfosfonates Osteoporose, tolerantie, werkzaamheid, bisfofonaten
Conditions
Interventions
Lichamelijk onderzoek, interview, bloed en urine onderzoek, invullen vragenlijsten.
Sponsors
Investigator initiated trial ( IIT )
Eligibility
Inclusion criteria
Inclusion criteria: 1. Postmenopausal women 50 yrs or >; 2. Diagnosed with osteoporosis as defined by: DEXA: T-score of-2.5 at lumbar spine or femoral neck os total hip, and or a vertebral fracture; 3. No treatment for osteoporosis in the 12 month before inclusion; 4. Ability to understand study procedures and to comply with them for the entire lenght of the study.
Exclusion criteria
Exclusion criteria: 1. Patients with prior teratment of osteoporosis (bisfofonates, testosterone, hormone replacement therapy( HRT) , selective estrogen receptor modulators ( SERMs) or calcitonin); 2. Patients who are previously intolerant of bisfosfonates; 3. Patients with disorders of esophageal motility or in whom oral bisfosfonates are contraindicated; 4. A history of upper GI tract disorder other than esophageal motility disorder is not a reason for exclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vergelijken van tolerantie en effectiviteit (dmv van vragenlijsten en botmarkers) van specialite alendronate ten opzichte van generiek alendronate. | — |
Contacts
Public ContactJ.P.W. Bergh, van den
Tegelseweg 210
Outcome results
None listed